Literature DB >> 11748195

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.

Giovanni Delogu1, Amy Li, Charlene Repique, Frank Collins, Sheldon L Morris.   

Abstract

DNA vaccination has emerged as a powerful approach in the search for a more efficacious vaccine against tuberculosis. In this study, we evaluated the effectiveness of immunizing with combinations of 10 different tuberculosis DNA vaccines that expressed mycobacterial proteins fused at the N terminus to eukaryotic intracellular targeting sequences. In one vaccine combination, the genes were fused to the tissue plasminogen activator signal sequence (TPA), while in a second combination the same 10 genes were expressed as ubiquitin (Ub)-conjugated proteins. In ex vivo studies in which the secretion of gamma interferon was measured, cellular immune responses were detected in mice vaccinated with either the TPA DNA vaccine combination or the Ub DNA vaccine combination at 7 and 14 days following a low-dose Mycobacterium tuberculosis challenge. Moreover, mice vaccinated with the TPA combination, the Ub combination, and Mycobacterium bovis BCG were able to limit the growth of tubercle bacilli in the lung and spleen after a virulent tuberculous aerosol challenge. Histopathological analyses also showed that mice immunized with the DNA vaccine combinations had substantially improved postinfection lung pathology relative to the naïve controls. Finally, in three different long-term experiments, the survival periods following aerogenic challenge were extended as much as sevenfold for vaccinated mice compared to naïve controls. Interestingly, in all three experiments, no significant differences were detected in the mean times to death for mice immunized with the TPA combination or the Ub combination relative to the BCG controls. In conclusion, these studies demonstrate the effectiveness of immunization with DNA vaccine combinations against tuberculosis and suggest that further testing of these plasmid cocktails is warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748195      PMCID: PMC127618          DOI: 10.1128/IAI.70.1.292-302.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.

Authors:  F Rodriguez; J Zhang; J L Whitton
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.

Authors:  Y Wu; T J Kipps
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

Review 3.  Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine.

Authors:  S H Kaufmann; P Andersen
Journal:  Chem Immunol       Date:  1998

4.  Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid.

Authors:  R Grifantini; O Finco; E Bartolini; M Draghi; G Del Giudice; C Kocken; A Thomas; S Abrignani; G Grandi
Journal:  Eur J Immunol       Date:  1998-04       Impact factor: 5.532

5.  Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

Authors:  T M Fu; J B Ulmer; M J Caulfield; R R Deck; A Friedman; S Wang; X Liu; J J Donnelly; M A Liu
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

Review 6.  Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis.

Authors:  P Andersen
Journal:  Scand J Immunol       Date:  1997-02       Impact factor: 3.487

7.  Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination.

Authors:  J B Ulmer; M A Liu; D L Montgomery; A M Yawman; R R Deck; C M DeWitt; J Content; K Huygen
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

8.  Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses.

Authors:  J Hinkula; P Lundholm; B Wahren
Journal:  Vaccine       Date:  1997-06       Impact factor: 3.641

9.  Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis.

Authors:  C Manca; K Lyashchenko; H G Wiker; D Usai; R Colangeli; M L Gennaro
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

10.  Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs.

Authors:  Z Li; C Kelley; F Collins; D Rouse; S Morris
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

View more
  25 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

Review 2.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 3.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  The hbhA gene of Mycobacterium tuberculosis is specifically upregulated in the lungs but not in the spleens of aerogenically infected mice.

Authors:  Giovanni Delogu; Maurizio Sanguinetti; Brunella Posteraro; Stefano Rocca; Stefania Zanetti; Giovanni Fadda
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen.

Authors:  Marcela Parra; Nathalie Cadieux; Thames Pickett; Veerabadran Dheenadhayalan; Michael J Brennan
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.

Authors:  Steven C Derrick; Teresa H Evering; Vasan K Sambandamurthy; Kripa V Jalapathy; Tsungda Hsu; Bing Chen; Mei Chen; Robert G Russell; Ana Paula Junqueira-Kipnis; Ian M Orme; Steven A Porcelli; William R Jacobs; Sheldon L Morris
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

7.  Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis.

Authors:  Steven C Derrick; Charlene Repique; Philip Snoy; Amy Li Yang; Sheldon Morris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

8.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

9.  Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis.

Authors:  Marcela Parra; Amy L Yang; JaeHyun Lim; Kristopher Kolibab; Steven Derrick; Nathalie Cadieux; Liyanage P Perera; William R Jacobs; Michael Brennan; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2009-05-20

10.  Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection.

Authors:  Ying Wu; Joshua S Woodworth; Daniel S Shin; Sheldon Morris; Samuel M Behar
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.